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Routine Elective Cesarean
Section Is Not Justified for
Women With Mechanical Heart Valves
We congratulate Vitale et al. (1) for providing substantive evidence
for a dose-dependent effect on adverse fetal outcome in pregnan-
cies complicated by maternal warfarin therapy. In the United
Kingdom, warfarin embryopathy is rare (2), and recently reported
cases have occurred almost exclusively in women taking large
(.9 mg) doses of warfarin (3). We agree with Vitale et al. (1) that
the small risk of embryopathy (3.4% in their series), which may be
confined to those requiring .5 mg to maintain an adequate
International Normalized Ratio (INR), should not be used as a
justification for recommending that women with prosthetic valves
be managed with heparin throughout their pregnancy, as some
have suggested (4). Indeed, an increased incidence of valve thrombosis
in pregnant women with mechanical valves (albeit mostly older-
generation prostheses in the mitral position) (5), managed with
subcutaneous heparin versus warfarin, has been reported (6). How-
ever, Vitale et al. (1) have highlighted the risks of spontaneous
miscarriage and stillbirth in warfarin-managed pregnancies and have
demonstrated that this too is dose-dependent.
We have two concerns: First is delivery with only brief (two-
day) discontinuation of warfarin therapy. As Vitale et al. pointed
out, the immature fetal liver may not only lead to over-
anticoagulation of the fetus despite a normal INR in the mother,
but also slow clearance of warfarin by the fetus, leading to
continued anticoagulation for up to 10 days after the mother stops
taking warfarin. Although there were no cases of neonatal hem-
orrhage in this series, despite the fact that warfarin was almost
certainly still present in the fetuses at the time of delivery, the
numbers are small and only three babies in the .5 mg group had
reached full term; second is the policy of routine elective cesarean
section at 38 weeks. We do not agree that elective cesarean section
“reduces the risk of perinatal intracranial hemorrhage in the fetus.”
The arguments have been well rehearsed for other maternal
conditions such as autoimmune thrombocytopenic purpura (7) and
hemophilia carriers (8), when there may be a risk of intracranial
hemorrhage in the baby. Indeed, neonatal intracranial hemorrhage
is described after cesarean section in both conditions, and the
current advice is to recommend vaginal delivery (7,8). Pregnancy
increases the risk of valve thrombosis. The time of greatest risk for
venous thrombosis is immediately after delivery, and cesarean
section further increases the risk up to 25-fold (9). We agree with
Elkayam (5), and it is our policy to discontinue warfarin and start
intravenous heparin, which does not cross the placenta and has a
very short half-life, at 36 weeks in preparation for induction of
labor or cesarean section at 38 weeks. We reserve cesarean section
for the usual obstetric indications. Because Vitale et al. (1) state
that “if the patient [on ,5 mg of warfarin] prefers to have vaginal
delivery, intravenous heparin over the last two weeks of gestation
should be offered as an option,” we assume that they deem this to
be a safe alternative. We would suggest that perhaps the emphasis
should be reversed from routine cesarean section to routine vaginal
delivery.
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REPLY
We read with great interest the letter by Nelson-Piercy et al.
regarding our article (1). They gave us the benefit of their
experience.
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We appreciate the points raised by them—that is, their concern
about the discontinuation of warfarin only two days before cesar-
ean section and the consequent hemorrhagic risks for the fetus.
Pregnancy increases the risk of valve thrombosis (2); therefore,
we had two main concerns at the time we devised our policy for
pregnant women with mechanical valves: 1) protecting the mother
from valve thrombosis; and 2) reducing the risk of fetal compli-
cations as much as possible.
Undoubtedly, warfarin is considered to be the best anticoagulant
agent for patients with mechanical valves (3). Even though
intravenous heparin has been used in the management of pregnant
women, the thromboembolic risk was found to be four to five times
higher for women taking heparin than for those taking an oral
anticoagulant agent (4). In our experience, in a general population,
we have observed a higher rate of thromboembolic and thrombotic
complications in patients with first- and second-generation me-
chanical valves as compared with bileaflet valves (5). Because 34 of
43 patients in our series had caged-ball or tilting disc valves, mostly
in the mitral position, we opted for the anticoagulation manage-
ment that enabled us to minimize the thrombotic risk during the
entire gestation period.
We agree that warfarin is still present in the fetus at the time of
cesarean section, but no hemorrhagic complications have been
observed in our series. Unfortunately, the International Normal-
ized Ratio (INR) levels in the babies were unknown, and therefore
it was difficult to assess the extent of anticoagulation in the fetus.
Ideally, the fetal INR should be checked soon after birth.
With respect to the authors’ concern for the fetus during
programmed cesarean section, we have not observed any untoward
effect of this procedure on the babies. Moreover, no deep vein
thromboses were observed in our patients, despite the high risk
pointed out by the authors.
Finally, with respect to their recommendation to use heparin at
36 weeks in preparation for induction of labor or cesarean section
at 38 weeks, we consider this policy applicable in selected patients.
We consider warfarin a better anticoagulant agent for patients with
first- and second-generation mechanical valves in the mitral
position. Therefore, we do not know whether heparin will yield
results as satisfactory as those with warfarin in reducing the
thrombotic risk in this subset of patients. In contrast, patients with
bileaflet valves may be managed with intravenous heparin during
their last two weeks of gestation, keeping in mind the side effects
of heparin (6) and the prolonged hospital stay.
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